| Year |
Citation |
Score |
| 2023 |
Su B, Vanham G. Effectiveness of COVID-19 primary and booster vaccination in HIV-infected individuals. Aids (London, England). 37: 837-839. PMID 36919787 DOI: 10.1097/QAD.0000000000003492 |
0.394 |
|
| 2021 |
Adams P, Fievez V, Schober R, Amand M, Iserentant G, Rutsaert S, Dessilly G, Vanham G, Hedin F, Cosma A, Moutschen M, Vandekerckhove L, Seguin-Devaux C. CD32CD4 memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. Iscience. 24: 101881. PMID 33364576 DOI: 10.1016/j.isci.2020.101881 |
0.404 |
|
| 2020 |
Adams P, Iserentant G, Servais JY, Vandekerckhove L, Vanham G, Seguin-Devaux C. Cytotoxic CD8+ T Cells Expressing CXCR5 Are Detectable in HIV-1 Elite Controllers After Prolonged Peptide Stimulation. Frontiers in Immunology. 11: 622343. PMID 33717056 DOI: 10.3389/fimmu.2020.622343 |
0.514 |
|
| 2020 |
Pannus P, Rutsaert S, De Wit S, Allard SD, Vanham G, Cole B, Nescoi C, Aerts J, De Spiegelaere W, Tsoumanis A, Couttenye MM, Herssens N, De Scheerder MA, Vandekerckhove L, Florence E. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription. Journal of the International Aids Society. 23: e25453. PMID 32107887 DOI: 10.1002/jia2.25453 |
0.435 |
|
| 2019 |
de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R. Correction to: iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 20: 721. PMID 31836017 DOI: 10.1186/s13063-019-3940-0 |
0.31 |
|
| 2019 |
Jong W, Leal L, Buyze J, Pannus P, Guardo A, Salgado M, Mothe B, Molto J, Moron-Lopez S, Gálvez C, Florence E, Vanham G, Gorp EV, Brander C, Allard S, et al. Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with HTI-TriMix. Vaccines. 7. PMID 31817794 DOI: 10.3390/vaccines7040209 |
0.373 |
|
| 2019 |
Pannus P, Vanham G. Viral Inhibitory Activity of CD8+ T Cells in HIV Infection. Aids Reviews. 21: 115-125. PMID 31532399 DOI: 10.24875/AIDSRev.19000068 |
0.523 |
|
| 2019 |
de Jong W, Aerts J, Allard S, Brander C, Buyze J, Florence E, van Gorp E, Vanham G, Leal L, Mothe B, Thielemans K, Plana M, Garcia F, Gruters R. iHIVARNA phase IIa, a randomized, placebo-controlled, double-blinded trial to evaluate the safety and immunogenicity of iHIVARNA-01 in chronically HIV-infected patients under stable combined antiretroviral therapy. Trials. 20: 361. PMID 31208472 DOI: 10.1186/s13063-019-3409-1 |
0.5 |
|
| 2019 |
Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G. In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients. Aids (London, England). 33: 387-398. PMID 30702513 DOI: 10.1097/QAD.0000000000002068 |
0.56 |
|
| 2018 |
Leal L, Guardo AC, Morón-López S, Salgado M, Mothe B, Heirman C, Pannus P, Vanham G, Ham HJVD, Gruters R, Andeweg A, Van Meirvenne S, Pich J, Arnaiz JA, Gatell JM, et al. Phase I clinical trial of an intranodally administered mRNA based therapeutic vaccine against HIV-1 infection. Aids (London, England). PMID 30289805 DOI: 10.1097/QAD.0000000000002026 |
0.384 |
|
| 2017 |
Adriaensen W, Dorlo TPC, Vanham G, Kestens L, Kaye PM, van Griensven J. Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients. Frontiers in Immunology. 8: 1943. PMID 29375567 DOI: 10.3389/fimmu.2017.01943 |
0.469 |
|
| 2017 |
Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, ... ... Vanham G, et al. Correction: Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. Plos Biology. 15: e1002608. PMID 28704367 DOI: 10.1371/journal.pbio.1002608 |
0.319 |
|
| 2017 |
Blanquart F, Wymant C, Cornelissen M, Gall A, Bakker M, Bezemer D, Hall M, Hillebregt M, Ong SH, Albert J, Bannert N, Fellay J, Fransen K, Gourlay AJ, Grabowski MK, ... ... Vanham G, et al. Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe. Plos Biology. 15: e2001855. PMID 28604782 DOI: 10.1371/Journal.Pbio.2001855 |
0.32 |
|
| 2017 |
Terrasse R, Memmi M, Palle S, Heyndrickx L, Vanham G, Pozzetto B, Bourlet T. Visualization of X4- and R5-Tropic HIV-1 Viruses Expressing Fluorescent Proteins in Human Endometrial Cells: Application to Tropism Study. Plos One. 12: e0169453. PMID 28060897 DOI: 10.1371/Journal.Pone.0169453 |
0.593 |
|
| 2016 |
Ariën KK, Baleux F, Desjardins D, Porrot F, Coïc YM, Michiels J, Bouchemal K, Bonnaffé D, Bruel T, Schwartz O, Le Grand R, Vanham G, Dereuddre-Bosquet N, Lortat-Jacob H. CD4-mimetic sulfopeptide conjugates display sub-nanomolar anti-HIV-1 activity and protect macaques against a SHIV162P3 vaginal challenge. Scientific Reports. 6: 34829. PMID 27721488 DOI: 10.1038/Srep34829 |
0.436 |
|
| 2016 |
Wang SX, Michiels J, Ariën KK, New R, Vanham G, Roitt I. Inhibition of HIV Virus by Neutralizing Vhh Attached to Dual Functional Liposomes Encapsulating Dapivirine. Nanoscale Research Letters. 11: 350. PMID 27465600 DOI: 10.1186/s11671-016-1558-7 |
0.398 |
|
| 2016 |
Tintori C, Brai A, Dasso Lang MC, Deodato D, Greco AM, Bizzarri BM, Cascone L, Casian A, Zamperini C, Dreassi E, Crespan E, Maga G, Vanham G, Ceresola E, Canducci F, et al. Development and in Vitro Evaluation of a Microbicide Gel Formulation for a Novel Non-Nucleoside Reverse Transcriptase Inhibitor Belonging to the N-Dihydroalkyloxybenzyloxopyrimidines (N-DABOs) Family. Journal of Medicinal Chemistry. 59: 2747-59. PMID 26898379 DOI: 10.1021/Acs.Jmedchem.5B01979 |
0.45 |
|
| 2016 |
Sergeyev S, Yadav AK, Franck P, Michiels J, Lewi P, Heeres J, Vanham G, Ariën KK, Vande Velde CM, De Winter H, Maes BU. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors. Journal of Medicinal Chemistry. 59: 1854-68. PMID 26785139 DOI: 10.1021/Acs.Jmedchem.5B01336 |
0.41 |
|
| 2016 |
Sergeyev S, Yadav AK, Franck P, Michiels J, Lewi P, Heeres J, Vanham G, Ariën KK, Vande Velde CML, De Winter H, Maes BUW. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors Journal of Medicinal Chemistry. 59: 1854-1868. DOI: 10.1021/acs.jmedchem.5b01336 |
0.402 |
|
| 2015 |
Kyongo JK, Crucitti T, Menten J, Hardy L, Cools P, Michiels J, Delany-Moretlwe S, Mwaura M, Ndayisaba G, Joseph S, Fichorova R, van de Wijgert J, Vanham G, Ariën KK, Jespers V. Cross-Sectional Analysis of Selected Genital Tract Immunological Markers and Molecular Vaginal Microbiota in Sub-Saharan African Women, with Relevance to HIV Risk and Prevention. Clinical and Vaccine Immunology : Cvi. 22: 526-38. PMID 25761460 DOI: 10.1128/Cvi.00762-14 |
0.341 |
|
| 2014 |
Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K. From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. Bioorganic & Medicinal Chemistry. 22: 5241-8. PMID 25199582 DOI: 10.1016/J.Bmc.2014.08.005 |
0.523 |
|
| 2014 |
Li X, Xue Y, Zhou L, Lin Y, Yu X, Wang X, Zhen X, Zhang W, Ning Z, Yue Q, Fu J, Shen F, Gai J, Xu Y, Mao J, ... ... Vanham G, et al. Evidence that HIV-1 CRF01_AE is associated with low CD4+T cell count and CXCR4 co-receptor usage in recently infected young men who have sex with men (MSM) in Shanghai, China. Plos One. 9: e89462. PMID 24586795 DOI: 10.1371/Journal.Pone.0089462 |
0.48 |
|
| 2014 |
Vanham G, Buvé A, Florence E, Seguin-Devaux C, Sáez-Cirión A. What is the significance of posttreatment control of HIV infection vis-à-vis functional cure? Aids (London, England). 28: 603-5. PMID 24401643 DOI: 10.1097/QAD.0000000000000147 |
0.456 |
|
| 2014 |
Grammen C, Ariën KK, Venkatraj M, Joossens J, Van der Veken P, Heeres J, Lewi PJ, Haenen S, Augustyns K, Vanham G, Augustijns P, Brouwers J. Development and in vitro evaluation of a vaginal microbicide gel formulation for UAMC01398, a novel diaryltriazine NNRTI against HIV-1. Antiviral Research. 101: 113-21. PMID 24269474 DOI: 10.1016/J.Antiviral.2013.11.005 |
0.502 |
|
| 2014 |
Huang C, Soenen SJ, van Gulck E, Rejman J, Vanham G, Lucas B, Geers B, Braeckmans K, Shahin V, Spanoghe P, Demeester J, De Smedt SC. Electrospun polystyrene fibers for HIV entrapment Polymers For Advanced Technologies. 25: 827-834. DOI: 10.1002/Pat.3310 |
0.439 |
|
| 2013 |
Heyndrickx L, Stewart-Jones G, Jansson M, Schuitemaker H, Bowles E, Buonaguro L, Grevstad B, Vinner L, Vereecken K, Parker J, Ramaswamy M, Biswas P, Vanham G, Scarlatti G, Fomsgaard A, et al. Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model. Plos One. 8: e74552. PMID 24023951 DOI: 10.1371/Journal.Pone.0074552 |
0.511 |
|
| 2013 |
Balla-Jhagjhoorsingh SS, Corti D, Heyndrickx L, Willems E, Vereecken K, Davis D, Vanham G. The N276 glycosylation site is required for HIV-1 neutralization by the CD4 binding site specific HJ16 monoclonal antibody. Plos One. 8: e68863. PMID 23874792 DOI: 10.1371/Journal.Pone.0068863 |
0.4 |
|
| 2013 |
Visciano ML, Tagliamonte M, Stewart-Jones G, Heyndrickx L, Vanham G, Jansson M, Fomsgaard A, Grevstad B, Ramaswamy M, Buonaguro FM, Tornesello ML, Biswas P, Scarlatti G, Buonaguro L. Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate. Journal of Translational Medicine. 11: 165. PMID 23835244 DOI: 10.1186/1479-5876-11-165 |
0.434 |
|
| 2013 |
Morellato-Castillo L, Acharya P, Combes O, Michiels J, Descours A, Ramos OH, Yang Y, Vanham G, Ariën KK, Kwong PD, Martin L, Kessler P. Interfacial cavity filling to optimize CD4-mimetic miniprotein interactions with HIV-1 surface glycoprotein. Journal of Medicinal Chemistry. 56: 5033-47. PMID 23710622 DOI: 10.1021/jm4002988 |
0.441 |
|
| 2013 |
Ariën KK, Venkatraj M, Michiels J, Joossens J, Vereecken K, Van der Veken P, Abdellati S, Cuylaerts V, Crucitti T, Heyndrickx L, Heeres J, Augustyns K, Lewi PJ, Vanham G. Diaryltriazine non-nucleoside reverse transcriptase inhibitors are potent candidates for pre-exposure prophylaxis in the prevention of sexual HIV transmission. The Journal of Antimicrobial Chemotherapy. 68: 2038-47. PMID 23645585 DOI: 10.1093/Jac/Dkt166 |
0.542 |
|
| 2013 |
Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, Binley JM, Ariën KK. M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding. Retrovirology. 10: 12. PMID 23375046 DOI: 10.1186/1742-4690-10-12 |
0.811 |
|
| 2013 |
Pollard C, Rejman J, De Haes W, Verrier B, Van Gulck E, Naessens T, De Smedt S, Bogaert P, Grooten J, Vanham G, De Koker S. Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 251-9. PMID 23011030 DOI: 10.1038/Mt.2012.202 |
0.303 |
|
| 2013 |
De Haes W, Rejman J, Pollard C, Merlin C, Vekemans M, Florence E, De Smedt SC, Grooten J, Vanham G, De Koker S, Van Gulck E. Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. Nanomedicine (London, England). 8: 77-87. PMID 22891862 DOI: 10.2217/nnm.12.97 |
0.334 |
|
| 2012 |
Dereuddre-Bosquet N, Morellato-Castillo L, Brouwers J, Augustijns P, Bouchemal K, Ponchel G, Ramos OH, Herrera C, Stefanidou M, Shattock R, Heyndrickx L, Vanham G, Kessler P, Le Grand R, Martin L. MiniCD4 microbicide prevents HIV infection of human mucosal explants and vaginal transmission of SHIV(162P3) in cynomolgus macaques. Plos Pathogens. 8: e1003071. PMID 23236282 DOI: 10.1371/journal.ppat.1003071 |
0.459 |
|
| 2012 |
Venkatraj M, Ariën KK, Heeres J, Joossens J, Messagie J, Michiels J, Van der Veken P, Vanham G, Lewi PJ, Augustyns K. Synthesis, evaluation and structure-activity relationships of triazine dimers as novel antiviral agents. Bioorganic & Medicinal Chemistry Letters. 22: 7174-8. PMID 23084903 DOI: 10.1016/J.Bmcl.2012.09.066 |
0.392 |
|
| 2012 |
Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN, Crucitti T, Vanham G, Ariën KK. Searching for lower female genital tract soluble and cellular biomarkers: defining levels and predictors in a cohort of healthy Caucasian women. Plos One. 7: e43951. PMID 22952818 DOI: 10.1371/Journal.Pone.0043951 |
0.358 |
|
| 2012 |
De Haes W, Van Mol G, Merlin C, De Smedt SC, Vanham G, Rejman J. Internalization of mRNA lipoplexes by dendritic cells. Molecular Pharmaceutics. 9: 2942-9. PMID 22894540 DOI: 10.1021/Mp3003336 |
0.432 |
|
| 2012 |
Van Gulck E, Cools N, Atkinson D, Bracke L, Vereecken K, Vekemans M, Van Tendeloo VF, Berneman ZN, Vanham G. Interleukin-12p70 expression by dendritic cells of HIV-1-infected patients fails to stimulate gag-specific immune responses. Clinical & Developmental Immunology. 2012: 184979. PMID 22844321 DOI: 10.1155/2012/184979 |
0.558 |
|
| 2012 |
Singh M, Singh P, Gaudray G, Musumeci L, Thielen C, Vaira D, Vandergeeten C, Delacroix L, Van Gulck E, Vanham G, de Leval L, Rahmouni S, Moutschen M. An improved protocol for efficient engraftment in NOD/LTSZ-SCIDIL-2Rγnull mice allows HIV replication and development of anti-HIV immune responses. Plos One. 7: e38491. PMID 22675567 DOI: 10.1371/journal.pone.0038491 |
0.47 |
|
| 2012 |
Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G. Immune and viral correlates of "secondary viral control" after treatment interruption in chronically HIV-1 infected patients. Plos One. 7: e37792. PMID 22666392 DOI: 10.1371/Journal.Pone.0037792 |
0.55 |
|
| 2012 |
Romain G, van Gulck E, Epaulard O, Oh S, Li D, Zurawski G, Zurawski S, Cosma A, Adam L, Chapon C, Todorova B, Banchereau J, Dereuddre-Bosquet N, Vanham G, Le Grand R, et al. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. European Journal of Immunology. 42: 2019-30. PMID 22585548 DOI: 10.1002/Eji.201242478 |
0.411 |
|
| 2012 |
Grupping K, Selhorst P, Michiels J, Vereecken K, Heyndrickx L, Kessler P, Vanham G, Martin L, Ariën KK. MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency. Retrovirology. 9: 36. PMID 22551420 DOI: 10.1186/1742-4690-9-36 |
0.755 |
|
| 2012 |
Meuwissen PJ, Stolp B, Iannucci V, Vermeire J, Naessens E, Saksela K, Geyer M, Vanham G, Arien KK, Fackler OT, Verhasselt B. Identification of a highly conserved valine-glycine-phenylalanine amino acid triplet required for HIV-1 Nef function. Retrovirology. 9: 34. PMID 22537596 DOI: 10.1186/1742-4690-9-34 |
0.385 |
|
| 2012 |
Van den Bergh R, Morin S, Sass HJ, Grzesiek S, Vekemans M, Florence E, Tran HT, Imiru RG, Heyndrickx L, Vanham G, De Baetselier P, Raes G. Monocytes contribute to differential immune pressure on R5 versus X4 HIV through the adipocytokine visfatin/NAMPT. Plos One. 7: e35074. PMID 22493731 DOI: 10.1371/journal.pone.0035074 |
0.409 |
|
| 2012 |
Ariën KK, Kyongo JK, Vanham G. Ex vivo models of HIV sexual transmission and microbicide development. Current Hiv Research. 10: 73-8. PMID 22264048 |
0.381 |
|
| 2012 |
Lewi P, Heeres J, Ariën K, Venkatraj M, Joossens J, Van der Veken P, Augustyns K, Vanham G. Reverse transcriptase inhibitors as microbicides. Current Hiv Research. 10: 27-35. PMID 22264043 DOI: 10.2174/157016212799304643 |
0.434 |
|
| 2012 |
Quiñones-Mateu ME, Vanham G. HIV microbicides: where are we now? Current Hiv Research. 10: 1-2. PMID 22264039 |
0.487 |
|
| 2012 |
Talledo M, López G, Huyghe JR, Verdonck K, González E, Clark D, Vanham G, Gotuzzo E, Van Camp G, Van Laer L. Possible implication of NFKB1A and NKG2D genes in susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian patients infected with HTLV-1. Journal of Medical Virology. 84: 319-26. PMID 22170554 DOI: 10.1002/Jmv.22255 |
0.321 |
|
| 2012 |
Van Gulck E, Vlieghe E, Vekemans M, Van Tendeloo VF, Van De Velde A, Smits E, Anguille S, Cools N, Goossens H, Mertens L, De Haes W, Wong J, Florence E, Vanham G, Berneman ZN. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. Aids (London, England). 26: F1-12. PMID 22156965 DOI: 10.1097/Qad.0B013E32834F33E8 |
0.6 |
|
| 2012 |
Selhorst P, Grupping K, Bourlet T, Delézay O, Ariën KK, Vanham G. In vitro activities of candidate microbicides against cell-associated HIV. Antimicrobial Agents and Chemotherapy. 56: 805-15. PMID 22083472 DOI: 10.1128/Aac.05801-11 |
0.82 |
|
| 2012 |
Huang C, Soenen SJ, van Gulck E, Vanham G, Rejman J, Van Calenbergh S, Vervaet C, Coenye T, Verstraelen H, Temmerman M, Demeester J, De Smedt SC. Electrospun cellulose acetate phthalate fibers for semen induced anti-HIV vaginal drug delivery. Biomaterials. 33: 962-9. PMID 22018388 DOI: 10.1016/J.Biomaterials.2011.10.004 |
0.466 |
|
| 2011 |
Hijazi K, Wang Y, Scala C, Jeffs S, Longstaff C, Stieh D, Haggarty B, Vanham G, Schols D, Balzarini J, Jones IM, Hoxie J, Shattock R, Kelly CG. DC-SIGN increases the affinity of HIV-1 envelope glycoprotein interaction with CD4. Plos One. 6: e28307. PMID 22163292 DOI: 10.1371/Journal.Pone.0028307 |
0.496 |
|
| 2011 |
Balla-Jhagjhoorsingh SS, Willems B, Heyndrickx L, Heyndrickx L, Vereecken K, Janssens W, Seaman MS, Corti D, Lanzavecchia A, Davis D, Vanham G. Characterization of neutralizing profiles in HIV-1 infected patients from whom the HJ16, HGN194 and HK20 mAbs were obtained. Plos One. 6: e25488. PMID 22016769 DOI: 10.1371/Journal.Pone.0025488 |
0.43 |
|
| 2011 |
Venkatraj M, Ariën KK, Heeres J, Dirié B, Joossens J, Van Goethem S, Van der Veken P, Michiels J, Vande Velde CM, Vanham G, Lewi PJ, Augustyns K. Novel diarylpyridinones, diarylpyridazinones and diarylphthalazinones as potential HIV-1 nonnucleoside reverse transcriptase inhibitors (NNRTIs). Bioorganic & Medicinal Chemistry. 19: 5924-34. PMID 21930388 DOI: 10.1016/J.Bmc.2011.08.060 |
0.543 |
|
| 2011 |
Ariën KK, Vanham G, Gali Y. A dual-chamber model of the female genital tract to evaluate epithelial toxicity of candidate anti-HIV microbicides. Current Protocols in Cell Biology / Editorial Board, Juan S. Bonifacino ... [Et Al.]. Unit26.13. PMID 21898337 DOI: 10.1002/0471143030.cb2613s52 |
0.545 |
|
| 2011 |
Ariën KK, Jespers V, Vanham G. HIV sexual transmission and microbicides. Reviews in Medical Virology. 21: 110-33. PMID 21412935 DOI: 10.1002/Rmv.684 |
0.513 |
|
| 2011 |
Haldar B, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny MK, Nyambi P. Longitudinal study of primary HIV-1 isolates in drug-naïve individuals reveals the emergence of variants sensitive to anti-HIV-1 monoclonal antibodies. Plos One. 6: e17253. PMID 21383841 DOI: 10.1371/Journal.Pone.0017253 |
0.457 |
|
| 2011 |
Van Gulck E, Heyndrickx L, Bracke L, Coppens S, Florence E, Buvé A, Lewi P, Vanham G. Control of viral replication after cessation of HAART. Aids Research and Therapy. 8: 6. PMID 21314914 DOI: 10.1186/1742-6405-8-6 |
0.384 |
|
| 2011 |
Selhorst P, Vazquez AC, Terrazas-Aranda K, Michiels J, Vereecken K, Heyndrickx L, Weber J, Quiñones-Mateu ME, Ariën KK, Vanham G. Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides. Antimicrobial Agents and Chemotherapy. 55: 1403-13. PMID 21282453 DOI: 10.1128/Aac.01426-10 |
0.72 |
|
| 2011 |
Ariën KK, Gali Y, Vanham G. The “gatekeeper” hypothesis challenged in a human cervico-vaginal tissue model for HIV-1 transmission Mucosal Immunology. 4: 121-122. PMID 21150895 DOI: 10.1038/Mi.2010.45 |
0.501 |
|
| 2011 |
Van Gulck E, Van Tendeloo VF, Vlieghe E, Vekemans M, Van de Velde A, Smits E, Anguilie S, Cools N, Stein B, Nijs G, Goossens H, Mertens L, De Haes W, Merlin C, Atkinson D, ... ... Vanham G, et al. Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA Retrovirology. 8: P76. DOI: 10.1186/1742-4690-8-S2-P76 |
0.493 |
|
| 2011 |
Meuwissen P, Ariën K, Vandewalle I, Naessens E, Vanderstraeten H, Taghon T, Vanham G, Fackler O, Kirchhoff F, Saksela K, Verhasselt B. Nef interferes with development of thymic T cell precursors: differential mechanisms in HIV and SIV Retrovirology. 8. DOI: 10.1186/1742-4690-8-S2-P48 |
0.517 |
|
| 2011 |
Ariën KK, Venkatraj M, Míchiels J, Joossens J, der Veken P, Heeres J, Abdellati S, Cuylaerts V, Crucitti T, Lewi P, Augustyns K, Vanham G. Development of triazine non-nucleoside reverse transcriptase inhibitors for microbicidal applications Retrovirology. 8. DOI: 10.1186/1742-4690-8-S2-P1 |
0.427 |
|
| 2011 |
Vanham G. Can immunotherapy be useful for a « functional cure » of HIV infection? Retrovirology. 8. DOI: 10.1186/1742-4690-8-S2-O33 |
0.473 |
|
| 2011 |
Morales S, Rosado J, López G, Huyghe J, Verdonck K, González E, Tipismana M, Clark D, Vanham G, Gotuzzo E, Van Camp G, Van laer L, Talledo M. HLA-G 14 bp insertion/deletion polymorphism is not associated to proviral load levels and presence of HAM/TSP in Peruvian HTLV-1 infected individuals Retrovirology. 8. DOI: 10.1186/1742-4690-8-S1-A122 |
0.349 |
|
| 2010 |
Ariën KK, Vanham G. First real success for anti-HIV gel: a new start for HIV microbicides? Future Microbiology. 5: 1621-3. PMID 21133683 DOI: 10.2217/fmb.10.129 |
0.474 |
|
| 2010 |
van der Kuyl AC, Kozaczynska K, Ariën KK, Gali Y, Balázs VR, Dekker SJ, Zorgdrager F, Vanham G, Berkhout B, Cornelissen M. Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness. Retrovirology. 7: 60. PMID 20646276 DOI: 10.1186/1742-4690-7-60 |
0.549 |
|
| 2010 |
Dieltjens T, Willems B, Coppens S, Van Nieuwenhove L, Humbert M, Dietrich U, Heyndrickx L, Vanham G, Janssens W. Unravelling the antigenic landscape of the HIV-1 subtype A envelope of an individual with broad cross-neutralizing antibodies using phage display peptide libraries. Journal of Virological Methods. 169: 95-102. PMID 20637241 DOI: 10.1016/j.jviromet.2010.07.004 |
0.331 |
|
| 2010 |
Elinder M, Selhorst P, Vanham G, Oberg B, Vrang L, Danielson UH. Inhibition of HIV-1 by non-nucleoside reverse transcriptase inhibitors via an induced fit mechanism-Importance of slow dissociation and relaxation rates for antiviral efficacy. Biochemical Pharmacology. 80: 1133-40. PMID 20599774 DOI: 10.1016/J.Bcp.2010.06.035 |
0.751 |
|
| 2010 |
Jenabian MA, Saïdi H, Charpentier C, Bouhlal H, Schols D, Balzarini J, Bell TW, Vanham G, Bélec L. Differential activity of candidate microbicides against early steps of HIV-1 infection upon complement virus opsonization. Aids Research and Therapy. 7: 16. PMID 20546571 DOI: 10.1186/1742-6405-7-16 |
0.569 |
|
| 2010 |
Van den Bergh R, Florence E, Vlieghe E, Boonefaes T, Grooten J, Houthuys E, Tran HT, Gali Y, De Baetselier P, Vanham G, Raes G. Transcriptome analysis of monocyte-HIV interactions. Retrovirology. 7: 53. PMID 20546557 DOI: 10.1186/1742-4690-7-53 |
0.469 |
|
| 2010 |
Talledo M, López G, Huyghe JR, Verdonck K, González E, Clark D, Senitzer D, Vanham G, Gotuzzo E, Van Camp G, Van Laer L. Role of killer cell immunoglobulin-like receptor gene content and human leukocyte antigen-C group in susceptibility to human T-lymphotropic virus 1-associated myelopathy/tropical spastic paraparesis in Peru. Human Immunology. 71: 804-8. PMID 20483367 DOI: 10.1016/J.Humimm.2010.05.011 |
0.336 |
|
| 2010 |
De Haes W, De Koker S, Pollard C, Atkinson D, Vlieghe E, Hoste J, Rejman J, De Smedt S, Grooten J, Vanham G, Van Gulck E. Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1408-16. PMID 20461059 DOI: 10.1038/Mt.2010.82 |
0.54 |
|
| 2010 |
Van Gulck E, Van Tendeloo VF, Berneman ZN, Vanham G. Role of dendritic cells in HIV-immunotherapy. Current Hiv Research. 8: 310-22. PMID 20353393 |
0.468 |
|
| 2010 |
Gali Y, Ariën KK, Praet M, Van den Bergh R, Temmerman M, Delezay O, Vanham G. Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. Journal of Virological Methods. 165: 186-97. PMID 20138087 DOI: 10.1016/j.jviromet.2010.01.018 |
0.48 |
|
| 2010 |
Talledo M, López G, Huyghe JR, Verdonck K, Adaui V, González E, Best I, Clark D, Vanham G, Gotuzzo E, Van Camp G, Van Laer L. Evaluation of host genetic and viral factors as surrogate markers for HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian HTLV-1-infected patients. Journal of Medical Virology. 82: 460-6. PMID 20087941 DOI: 10.1002/Jmv.21675 |
0.318 |
|
| 2009 |
Dieltjens T, Heyndrickx L, Willems B, Gray E, Van Nieuwenhove L, Grupping K, Vanham G, Janssens W. Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies. Retrovirology. 6: 113. PMID 20003438 DOI: 10.1186/1742-4690-6-113 |
0.484 |
|
| 2009 |
Jenabian MA, Saïdi H, Charpentier C, Van Herrewege Y, Son JC, Schols D, Balzarini J, Vanham G, Bélec L. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20). The Journal of Antimicrobial Chemotherapy. 64: 1192-5. PMID 19875507 DOI: 10.1093/jac/dkp380 |
0.798 |
|
| 2009 |
Jallow S, Vincent T, Leligdowicz A, De Silva T, Van Tienen C, Alabi A, Sarge-Njie R, Aaby P, Corrah T, Whittle H, Jaye A, Vanham G, Rowland-Jones S, Janssens W. Presence of a multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naive individual in Caio, Guinea Bissau. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 48: 1790-3. PMID 19438401 DOI: 10.1086/599107 |
0.393 |
|
| 2009 |
Jallow S, Alabi A, Sarge-Njie R, Peterson K, Whittle H, Corrah T, Jaye A, Cotten M, Vanham G, McConkey SJ, Rowland-Jones S, Janssens W. Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants. Journal of Clinical Microbiology. 47: 2200-8. PMID 19420165 DOI: 10.1128/Jcm.01654-08 |
0.603 |
|
| 2009 |
Verdonck K, González E, Maldonado F, Agapito D, Van Dooren S, Vandamme AM, Silva-Santisteban A, Vanham G, Clark D, Gotuzzo E. Comparison of three ELISAs for the routine diagnosis of human T-lymphotropic virus infection in a high-prevalence setting in Peru. Transactions of the Royal Society of Tropical Medicine and Hygiene. 103: 420-2. PMID 19155035 DOI: 10.1016/J.Trstmh.2008.12.002 |
0.313 |
|
| 2009 |
Dieltjens T, Willems B, Heyndrickx L, Vanham G. P04-34. Identification of 4E10-like antibodies in plasma of an HIV-1 CRF02_AG infected patient with broad neutralizing activity using peptide phage libraries Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P62 |
0.331 |
|
| 2009 |
Nyambi P, Burda S, Williams C, Heyndrickx L, Vanham G, Gorny M. P04-14. Sequential HIV-1 isolates from infected individuals reveals emergence of neutralization sensitive HIV-1 strains in the course of infection Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P42 |
0.478 |
|
| 2009 |
Balla-Jhagjhoorsingh S, Willems B, Vereecken K, Heyndrickx L, Davis D, Corti D, Lanzavecchia A, Weiss R, Vanham G. P04-52 LB. The importance of well-defined HIV-1 neutralization assays Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P392 |
0.341 |
|
| 2009 |
Njai H, Tomusange K, Sokolik-Wolak B, Montefiori D, Balla S, Vanham G, Levin J, Maher D, Kamali A, Grosskurth H, Pala P, Kaleebu P. P04-11. Prevalence of neutralizing antibody responses in chronic clades A and D human immunodeficiency virus type 1 (HIV-1) infections Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P39 |
0.398 |
|
| 2009 |
Romain G, Van Gulck E, Zurawski G, Banchereau J, Vanham G, Le Grand R, Martinon F. P18-08. Characterization of CD34+ derived dendritic cells generated in vitro and transfected with HIV gene as potential therapeutic vaccine in macaque Retrovirology. 6: P317. DOI: 10.1186/1742-4690-6-S3-P317 |
0.419 |
|
| 2009 |
Grupping K, Heyndrickx L, Michiels J, Martin G, Martin L, Vanham G. P12-11. Resistance to the CD4 mimetic mini protein M48-U1 induces changes in a highly conserved region on the HIV-1 gp120 envelope protein Retrovirology. 6. DOI: 10.1186/1742-4690-6-S3-P177 |
0.353 |
|
| 2009 |
Bergh RVd, Raes G, Vekemans M, Florence E, Tran HTT, Gali Y, Vanham G, De Baetselier P. Do monocytes use the novel adipocytokine Visfatin/NAMPT/PBEF1 to flip the HIV coreceptor switch? Retrovirology. 6. DOI: 10.1186/1742-4690-6-S2-P88 |
0.596 |
|
| 2008 |
Nyambi P, Burda S, Urbanski M, Heyndrickx L, Janssens W, Vanham G, Nadas A. Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals. Aids Research and Human Retroviruses. 24: 1507-19. PMID 19018670 DOI: 10.1089/Aid.2008.0154 |
0.346 |
|
| 2008 |
Terrazas-Aranda K, Van Herrewege Y, Hazuda D, Lewi P, Costi R, Di Santo R, Cara A, Vanham G. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection. Antimicrobial Agents and Chemotherapy. 52: 2544-54. PMID 18474579 DOI: 10.1128/Aac.01627-07 |
0.817 |
|
| 2008 |
Vermeire K, Brouwers J, Van Herrewege Y, Le Grand R, Vanham G, Augustijns P, Bell TW, Schols D. CADA, a potential anti-HIV microbicide that specifically targets the cellular CD4 receptor. Current Hiv Research. 6: 246-56. PMID 18473788 DOI: 10.1016/J.Antiviral.2009.02.161 |
0.826 |
|
| 2008 |
Van Herrewege Y, Morellato L, Descours A, Aerts L, Michiels J, Heyndrickx L, Martin L, Vanham G. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. The Journal of Antimicrobial Chemotherapy. 61: 818-26. PMID 18270220 DOI: 10.1093/jac/dkn042 |
0.795 |
|
| 2008 |
Van Gulck ER, Vanham G, Heyndrickx L, Coppens S, Vereecken K, Atkinson D, Florence E, Kint I, Berneman ZN, Van Tendeloo V. Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals. Journal of Virology. 82: 3561-73. PMID 18234800 DOI: 10.1128/Jvi.02080-07 |
0.582 |
|
| 2008 |
Heyndrickx L, Vermoesen T, Vereecken K, Kurth J, Coppens S, Aerts L, Ohagen A, Van Herrewege Y, Lewi P, Vanham G. Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays. Journal of Virological Methods. 148: 166-73. PMID 18192031 DOI: 10.1016/j.jviromet.2007.11.009 |
0.783 |
|
| 2008 |
Beels D, Heyndrickx L, Vereecken K, Vermoesen T, Michiels L, Vanham G, Kestens L. Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes. Journal of Virological Methods. 147: 99-107. PMID 17904649 DOI: 10.1016/J.Jviromet.2007.08.014 |
0.549 |
|
| 2007 |
Terrazas-Aranda K, Van Herrewege Y, Lewi PJ, Van Roey J, Vanham G. In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection. Antiviral Chemistry & Chemotherapy. 18: 141-51. PMID 17626598 DOI: 10.1177/095632020701800304 |
0.82 |
|
| 2007 |
Jespers V, Laga M, Van Herrewege Y, Vanham G. Microbicides a long and bumpy road to success? Aids Reviews. 9: 61-2. PMID 17474314 |
0.652 |
|
| 2007 |
Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM, Lee FH, Richman DD, Doms RW, Vanham G, Burton DR. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. Journal of Virology. 81: 6548-62. PMID 17409160 DOI: 10.1128/Jvi.02749-06 |
0.364 |
|
| 2007 |
Gali Y, Berkhout B, Vanham G, Bakker M, Back NK, Ariën KK. Survey of the temporal changes in HIV-1 replicative fitness in the Amsterdam Cohort. Virology. 364: 140-6. PMID 17395236 DOI: 10.1016/j.virol.2007.02.021 |
0.438 |
|
| 2007 |
Steyaert S, Heyndrickx L, Verhoye L, Vermoesen T, Donners H, Fransen K, Van Wanzeele F, Vandergucht B, Vanham G, Leroux-Roels G, Vanlandschoot P. Inhibition of replication of primary HIV-1 isolates in huPBL-NOD/Scid mice by antibodies from HIV-1 infected patients. Antiviral Research. 75: 129-38. PMID 17379323 DOI: 10.1016/J.Antiviral.2006.10.013 |
0.536 |
|
| 2007 |
Verdonck K, González E, Van Dooren S, Vandamme AM, Vanham G, Gotuzzo E. Human T-lymphotropic virus 1: recent knowledge about an ancient infection. The Lancet. Infectious Diseases. 7: 266-81. PMID 17376384 DOI: 10.1016/S1473-3099(07)70081-6 |
0.391 |
|
| 2007 |
Jallow S, Kaye S, Schutten M, Brandin E, Albert J, McConkey SJ, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. Journal of Clinical Microbiology. 45: 1565-71. PMID 17329450 DOI: 10.1128/JCM.02220-06 |
0.393 |
|
| 2007 |
Steyaert S, Verhoye L, Beirnaert E, Donners H, Fransen K, Heyndrickx L, Vanham G, Leroux-Roels G, Vanlandschoot P. The intraspleen huPBL NOD/SCID model to study the human HIV-specific antibody response selected in the course of natural infection. Journal of Immunological Methods. 320: 49-57. PMID 17258763 DOI: 10.1016/J.Jim.2006.12.003 |
0.498 |
|
| 2007 |
Ariën KK, Vanham G, Arts EJ. Is HIV-1 evolving to a less virulent form in humans? Nature Reviews. Microbiology. 5: 141-51. PMID 17203103 DOI: 10.1038/Nrmicro1594 |
0.476 |
|
| 2007 |
Van Herrewege Y, Michiels J, Waeytens A, De Boeck G, Salden E, Heyndrickx L, van den Mooter G, de Béthune MP, Andries K, Lewi P, Praet M, Vanham G. A dual chamber model of female cervical mucosa for the study of HIV transmission and for the evaluation of candidate HIV microbicides. Antiviral Research. 74: 111-24. PMID 17097156 DOI: 10.1016/j.antiviral.2006.10.010 |
0.832 |
|
| 2007 |
Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Molecular Pharmacology. 71: 3-11. PMID 17056872 DOI: 10.1124/mol.106.030155 |
0.808 |
|
| 2006 |
Van den Bosch GA, Van Gulck E, Ponsaerts P, Nijs G, Lenjou M, Apers L, Kint I, Heyndrickx L, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Simultaneous activation of viral antigen-specific memory CD4+ and CD8+ T-cells using mRNA-electroporated CD40-activated autologous B-cells. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 512-23. PMID 16971807 DOI: 10.1097/01.cji.0000210385.48327.1e |
0.432 |
|
| 2006 |
Njai HF, Gali Y, Vanham G, Clybergh C, Jennes W, Vidal N, Butel C, Mpoudi-Ngolle E, Peeters M, Ariën KK. The predominance of Human Immunodeficiency Virus type 1 (HIV-1) circulating recombinant form 02 (CRF02_AG) in West Central Africa may be related to its replicative fitness. Retrovirology. 3: 40. PMID 16817969 DOI: 10.1186/1742-4690-3-40 |
0.569 |
|
| 2006 |
Jallow S, Kaye S, Alabi A, Aveika A, Sarge-Njie R, Sabally S, Corrah T, Whittle H, Vanham G, Rowland-Jones S, Janssens W, McConkey SJ. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. Aids (London, England). 20: 1455-8. PMID 16791023 DOI: 10.1097/01.aids.0000233582.64467.8e |
0.351 |
|
| 2006 |
Van den Bosch GA, Ponsaerts P, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF. Cellular immunotherapy for cytomegalovirus and HIV-1 infection. Journal of Immunotherapy (Hagerstown, Md. : 1997). 29: 107-21. PMID 16531812 DOI: 10.1097/01.cji.0000184472.28832.d3 |
0.466 |
|
| 2006 |
Ariën KK, Gali Y, El-Abdellati A, Heyndrickx L, Janssens W, Vanham G. Replicative fitness of CCR5-using and CXCR4-using human immunodeficiency virus type 1 biological clones. Virology. 347: 65-74. PMID 16386774 DOI: 10.1016/J.Virol.2005.11.045 |
0.522 |
|
| 2006 |
Van Gulck ER, Ponsaerts P, Heyndrickx L, Vereecken K, Moerman F, De Roo A, Colebunders R, Van den Bosch G, Van Bockstaele DR, Van Tendeloo VF, Allard S, Verrier B, Marañón C, Hoeffel G, Hosmalin A, ... ... Vanham G, et al. Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. Blood. 107: 1818-27. PMID 16263796 DOI: 10.1182/Blood-2005-01-0339 |
0.514 |
|
| 2006 |
Jallow S, Kaye S, Brandin E, Albert J, Vanham G, Whittle H, Rowland-Jones S, Janssens W. Development and evaluation of the oligonucleotide ligation assay (OLA) for the detection of drug resistance mutations in HIV-2 patients on antiretroviral therapy Retrovirology. 3. DOI: 10.1186/1742-4690-3-S1-P29 |
0.351 |
|
| 2006 |
Vanham G. Are HIV-specific CD4 + T cells useless? Blood. 107: 1253-1253. DOI: 10.1182/Blood-2005-11-4636 |
0.559 |
|
| 2005 |
Ariën KK, Troyer RM, Gali Y, Colebunders RL, Arts EJ, Vanham G. Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time. Aids (London, England). 19: 1555-64. PMID 16184024 DOI: 10.1097/01.Aids.0000185989.16477.91 |
0.496 |
|
| 2005 |
Troyer RM, Collins KR, Abraha A, Fraundorf E, Moore DM, Krizan RW, Toossi Z, Colebunders RL, Jensen MA, Mullins JI, Vanham G, Arts EJ. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. Journal of Virology. 79: 9006-18. PMID 15994794 DOI: 10.1128/Jvi.79.14.9006-9018.2005 |
0.499 |
|
| 2005 |
Ariën KK, Abraha A, Quiñones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. Journal of Virology. 79: 8979-90. PMID 15994792 DOI: 10.1128/Jvi.79.14.8979-8990.2005 |
0.569 |
|
| 2005 |
Njai HF, Lewi PJ, Janssen CG, Garcia S, Fransen K, Kestens L, Vanham G, Janssen PA. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells. Antiviral Therapy. 10: 255-62. PMID 15865220 |
0.554 |
|
| 2005 |
Berneman ZN, Gulck ERAV, Bosch GVd, Ponsaerts P, Heyndrickx L, Moerman F, Roo AD, Lenjou M, Nijs G, Bockstaele DRV, Tendeloo VFIV, Maranon C, Hosmalin A, Vanham G. Activation of HIV-1-Specific CD8+ and CD4+ Autologous Memory T-Cells by Dendritic Cells and B-Cells Electroporated with mRNA Encoding Consensus or Autologous HIV-1 Proteins. Blood. 106: 326-326. DOI: 10.1182/Blood.V106.11.326.326 |
0.582 |
|
| 2004 |
Van Herrewege Y, Vanham G, Michiels J, Fransen K, Kestens L, Andries K, Janssen P, Lewi P. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides. Antimicrobial Agents and Chemotherapy. 48: 3684-9. PMID 15388420 DOI: 10.1128/Aac.48.10.3684-3689.2004 |
0.807 |
|
| 2004 |
Davis D, Donners H, Willems B, Lövgren-Bengtsson K, Akerblom L, Vanham G, Barnett S, Morein B, Heeney JL, van der Groen G. Neutralization of primary HIV-1 SF13 can be detected in extended incubation phase assays with sera from monkeys immunized with recombinant HIV-1 SF2 gp120. Vaccine. 22: 747-54. PMID 14741168 |
0.422 |
|
| 2004 |
Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G, Janssen P. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrobial Agents and Chemotherapy. 48: 337-9. PMID 14693562 DOI: 10.1128/Aac.48.1.337-339.2004 |
0.813 |
|
| 2003 |
Weber J, Rangel HR, Chakraborty B, Marotta ML, Valdez H, Fransen K, Florence E, Connick E, Smith KY, Colebunders RL, Landay A, Kuritzkes DR, Lederman MM, Vanham G, Quiñones-Mateu ME. Role of Baseline pol Genotype in HIV-1 Fitness Evolution. Journal of Acquired Immune Deficiency Syndromes (1999). 33: 448-60. PMID 12869833 DOI: 10.1097/00126334-200308010-00005 |
0.447 |
|
| 2002 |
Balzarini J, Van Herrewege Y, Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. Aids (London, England). 16: 2159-63. PMID 12409737 |
0.804 |
|
| 2002 |
Van Herrewege Y, Penne L, Vereecken C, Fransen K, van der Groen G, Kestens L, Balzarini J, Vanham G. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission. Aids Research and Human Retroviruses. 18: 1091-102. PMID 12396448 DOI: 10.1089/088922202320567833 |
0.8 |
|
| 2001 |
Mayanja-Kizza H, Wajja A, Wu M, Peters P, Nalugwa G, Mubiru F, Aung H, Vanham G, Hirsch C, Whalen C, Ellner J, Toossi Z. Activation of beta-chemokines and CCR5 in persons infected with human immunodeficiency virus type 1 and tuberculosis. The Journal of Infectious Diseases. 183: 1801-4. PMID 11372034 DOI: 10.1086/320724 |
0.503 |
|
| 2000 |
Colebunders R, Fransen K, Florence E, Vanham G. HIV-1 viral load and scrub typhus. Lancet (London, England). 356: 1765-6; author reply. PMID 11095278 DOI: 10.1016/S0140-6736(05)71953-X |
0.441 |
|
| 2000 |
Vanham G, Penne L, Allemeersch H, Kestens L, Willems B, van der Groen G, Jeang KT, Toossi Z, Rich E. Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation. Aids (London, England). 14: 2299-311. PMID 11089618 DOI: 10.1097/00002030-200010200-00011 |
0.544 |
|
| 2000 |
Quiñones-Mateu ME, Ball SC, Marozsan AJ, Torre VS, Albright JL, Vanham G, van Der Groen G, Colebunders RL, Arts EJ. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. Journal of Virology. 74: 9222-33. PMID 10982369 DOI: 10.1128/Jvi.74.19.9222-9233.2000 |
0.558 |
|
| 2000 |
Vanham G, van Tendeloo V, Willems B, Penne L, Kestens L, Beirnaert E, Fransen K, Heyndrickx L, Zhong P, Davis D, Berneman Z, van Der Groen G, Van Bockstaele D. The HIV-2 genotype and the HIV-1 syncytium-inducing phenotype are associated with a lower virus replication in dendritic cells. Journal of Medical Virology. 60: 300-12. PMID 10630963 DOI: 10.1002/(Sici)1096-9071(200003)60:3<300::Aid-Jmv9>3.0.Co;2-G |
0.568 |
|
| 1998 |
Vingerhoets J, Bisalinkumi E, Penne G, Colebunders R, Bosmans E, Kestens L, Vanham G. Altered receptor expression and decreased sensitivity of T-cells to the stimulatory cytokines IL-2, IL-7 and IL-12 in HIV infection Immunology Letters. 61: 53-61. PMID 9562375 DOI: 10.1016/S0165-2478(97)00162-4 |
0.312 |
|
| 1997 |
Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease. 78: 145-58. PMID 9713647 DOI: 10.1016/S0962-8479(97)90021-6 |
0.331 |
|
| 1996 |
Vanham G, Edmonds K, Qing L, Hom D, Toossi Z, Jones B, Daley CL, Huebner B, Kestens L, Gigase P, Ellner JJ. Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection. Clinical and Experimental Immunology. 103: 30-4. PMID 8565282 DOI: 10.1046/J.1365-2249.1996.907600.X |
0.458 |
|
| 1995 |
Zhong P, Peeters M, Janssens W, Fransen K, Heyndrickx L, Vanham G, Willems B, Piot P, van der Groen G. Correlation between genetic and biological properties of biologically cloned HIV type 1 viruses representing subtypes A, B, and D. Aids Research and Human Retroviruses. 11: 239-48. PMID 7742038 DOI: 10.1089/AID.1995.11.239 |
0.305 |
|
| 1995 |
Van Laer L, Vingerhoets J, Vanham G, Kestens L, Bwayo J, Otido J, Piot P, Roggen E. In vitro stimulation of peripheral blood mononuclear cells (PBMC) from HIV- and HIV+ chancroid patients by Haemophilus ducreyi antigens. Clinical and Experimental Immunology. 102: 243-50. PMID 7586673 DOI: 10.1111/J.1365-2249.1995.Tb03772.X |
0.458 |
|
| 1994 |
Vanham G, Kestens L, Vingerhoets J, Penne G, Colebunders R, Vandenbruaene M, Goeman J, Ceuppens JL, Sugamura K, Gigase P. The interleukin-2 receptor subunit expression and function on peripheral blood lymphocytes from HIV-infected and control persons. Clinical Immunology and Immunopathology. 71: 60-8. PMID 8137559 DOI: 10.1006/Clin.1994.1052 |
0.452 |
|
| 1994 |
Locher C, Vanham G, Kestens L, Kruger M, Ceuppens JL, Vingerhoets J. Expression patterns of Fcγ receptors, HLA-DR and selected adhesion molecules on monocytes from normal and HIV-infected individuals Clinical and Experimental Immunology. 98: 115-122. PMID 7923868 DOI: 10.1111/J.1365-2249.1994.Tb06616.X |
0.349 |
|
| 1994 |
De Meester I, Vanham G, Kestens L, Vanhoof G, Bosmans E, Gigase P, Scharpé S. Binding of adenosine deaminase to the lymphocyte surface via CD26. European Journal of Immunology. 24: 566-70. PMID 7907293 DOI: 10.1002/Eji.1830240311 |
0.336 |
|
| 1993 |
Vanham GL, Kestens L, Van Hoof J, Penne G, Colebunders R, Goilav C, Vandenbruaene M, el Habib R, Gigase P. Immunological parameters during treatment with ditiocarb (Imuthiol). Aids (London, England). 7: 525-30. PMID 8389559 DOI: 10.1097/00002030-199304000-00012 |
0.43 |
|
| 1992 |
Vanham G, Kestens L, Penne G, Goilav C, Gigase P, Colebunders R, Vandenbruaene M, Goeman J, van der Groen G, Ceuppens JL. Subset markers of CD8(+) cells and their relation to enhanced cytotoxic T-cell activity during human immunodeficiency virus infection. Journal of Clinical Immunology. 11: 345-56. PMID 1761640 DOI: 10.1007/Bf00918800 |
0.544 |
|
| 1990 |
Vanham G, Kestens L, Gigase P, Colebunders R, Vandenbruaene M, Brijs L, Ceuppens JL. Evidence for circulating activated cytotoxic T cells in HIV-infected subjects before the onset of opportunistic infections Clinical and Experimental Immunology. 82: 3-9. PMID 2208794 DOI: 10.1111/J.1365-2249.1990.Tb05395.X |
0.477 |
|
| Show low-probability matches. |